BeiGene still bleeding red ink despite blockbuster drug
The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
FAST NEWS: BeiGene Loss Narrows on Brisk Sales for Core Products
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday its revenue rose 20.4% last year to $1.42 billion, thanks to big increases from its two core products,…